According to a new report published by Allied Market Research, titled, “Netupitant Palonosetron Market: Global Opportunity Analysis and Industry Forecast, 2014–2022”, the global netupitant–palonosetron was valued at $257,162 million in 2015, and is expected to reach $527,187 million by 2022, growing at a CAGR of 10.8% from 2016 to 2022.

Summary of the Netupitant-Palonosetron Market Report can be accessed on the website at: https://www.alliedmarketresearch.com/netupitant-palonosetron-FDC-market

Netupitant–palonosetron FDC market holds a substantial scope for growth globally. The market is in its growth stage; however, its contribution to the global market is expected to increase significantly within the next six years. High cost is a major limitation to for the growth of the market in developing regions. However, recent innovations, which embed high potential and longer duration of action within the CINV drugs reach a wider segment of audiences. Numerous players are stepping in the CINV market with innovative products. Emerging technology such as novel drugs discovery and innovation of antiemetic therapy are expected to increase the competition in the near future.

KEY FINDINGS OF THE STUDY
• North America dominated the netupitant–palonosetron market, and is expected to grow at a CAGR of 9.9%.
• Asia-Pacific shows the highest growth rate, and is estimated to grow at a CAGR of 14.7%.
Key players profiled in this report include Acacia Pharma, Helsinn Holding S.A., Heron Therapeutics, Inc., and Eisai Pharmaceutical Pvt Ltd.

Summary of Similar Reports can be accessed at: https://www.alliedmarketresearch.com/life-sciences/medical-devices-market-report